IL37 and inflammatory bowel disease: Risankizumab is a humanized monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), blocking the IL-23/IL-17 inflammatory pathway that plays a crucial role in the pathogenesis of inflammatory bowel disease.